Skip to main content
. 2022 Dec 20;11(1):2. doi: 10.3390/vaccines11010002

Figure 5.

Figure 5

Biological effect of vaccine-induced antibodies. Plasma samples were obtained from groups (n = 8) of male BALB/c mice after three immunizations (3rd bleed) with cVLP-PCSK9(210–226), cVLP-PCSK9(156–227), cVLP-PCSK9(FL), PCSK9-SpyT or SpyC-cVLP. Data are depicted as the mean ± SD. (A). Total cholesterol (TC) level with mean ± SD measured in plasma from mice before vaccination (i.e., pre-bleed) (116 ± 8) or after vaccination with cVLP-PCSK9(210–226) (96.9 ± 15), cVLP-PCSK9(156–227) (98.9 ± 7), cVLP-PCSK9(FL) (92.9 ± 8) or soluble PCSK9-SpyT (105 ± 3). (B). Triglyceride level with mean ± SD detected in plasma obtained before vaccination (pre-bleed) (159 ± 67) or after vaccination with cVLP-PCSK8210-226) (115 ± 29), cVLP-PCSK9(156–227) (115 ± 59), cVLP-PCSK9(FL) (104 ± 22) or soluble PCSK9-SpyT (114 ± 31). (C). Quantitative total PCSK9 levels measured in plasma before vaccination (pre-bleed) (166 ± 18) or after vaccination with cVLP-PCSK9(210–226) (350 ± 170), cVLP-PCSK9(156–227) (290 ± 116), cVLP-PCSK9(FL) (102 ± 58.4) or SpyC-cVLP (143 ± 15.7). (D). Quantitative free PCSK9 levels detected in run through after purifying IgG from pooled plasma sample obtained from mice vaccinated with cVLP-PCSK9(210–226) (49.2 ng/mL), cVLP-PCSK9(156–227) (69.6 ng/mL), cVLP-PCSK9(FL) (16.1 ng/mL) or SpyC-cVLP (37.2 ng/mL). (E). Quantitative PCSK9 levels detected in 10 µg purified IgG from pooled plasma samples obtained from mice vaccinated with cVLP-PCSK9(210–226) (5.2 ng/mL), cVLP-PCSK9(156–227) (2.7 ng/mL), cVLP-PCSK9(FL) (2.1 ng/mL) or SpyC-cVLP (0.040 ng/mL). Statistical analysis was performed on log-transformed values using one-way ANOVA, Tukey’s multiple comparisons test and non-parametric, two-tailed, Mann–Whitney test (adjusted p-value < 0.05 was accepted as significant, ** < 0.05, *** < 0.001, **** < 0.0001).